" EXO Biologics plans to extend its research and development program towards the COVID-19 crisis by using its unique and disruptive technology based on Extracellular Vesicles. These nanometer size particles are gaining momentum in the scientific community as potential alternatives to stem cell and biologic drugs therapies in the fields of immunology, neurology, oncology, cardiology, gastroenterology among others. EXO Biologics has 12 years of experience in cell-based regenerative medicine and 8 years of experience in Extracellular Vesicles. Our advancements in research will play an important role for our company mission to provide affordable and accessible therapies to patients with unmet medical needs. "
Jurga Marcin, PhD